Prevention of experimental antiphospholipid syndrome and endothelial cell activation by synthetic peptides
Antiphospholipid syndrome (APS) is characterized by recurrent fetal loss, repeated thromboembolic phenomena, and thrombocytopenia. The syndrome is believed to be caused by antiphospholipid beta-2-glycoprotein-I (β2GPI)-dependent Abs or anti-β2GPI Abs by themselves. Using a hexapeptide phage display...
محفوظ في:
| الحاوية / القاعدة: | Proc Natl Acad Sci U S A |
|---|---|
| المؤلفون الرئيسيون: | , , , , , |
| التنسيق: | Artigo |
| اللغة: | Inglês |
| منشور في: |
National Academy of Sciences
1999
|
| الموضوعات: | |
| الوصول للمادة أونلاين: | https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC21834/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/10220436/ https://ncbi.nlm.nih.govhttps://doi.org/10.1073/pnas.96.9.5164 |
| الوسوم: |
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|